Concepedia

Safety and Immunogenicity of SARS-CoV-2 Vaccines in Patients With Chronic Liver Diseases (CHESS-NMCID 2101): A Multicenter Study

Jingwen Ai, Jitao Wang, Dengxiang Liu, Huiling Xiang, Ying Guo, Jiaojian Lv, Qiran Zhang, Jinlong Li, Xiaochong Zhang, Qianqian Li,

Clinical Gastroenterology and Hepatology · 2021 · 73 citations · 19 references

DOIFull text

Open access

Concepts

References

19

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Edward E. Walsh, Robert W. Frenck, Ann R. Falsey et al. · New England Journal of Medicine · 2020 · 2.7K citations · Full text

, , +17

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Yanjun Zhang, Gang Zeng, Hongxing Pan et al. · The Lancet Infectious Diseases · 2020 · 1.5K citations · Full text

, , +17

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

Fengcai Zhu, Yu-Hua Li, Xu-Hua Guan et al. · The Lancet · 2020 · 1.5K citations · Full text

, , +17

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

The Lancet · 2020 · 1.4K citations · Full text

, , +17

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Amy Ross-Russell, Nisha Singh · Oxford University Research Archive (ORA) (University of Oxford) · 2020 · 1.2K citations · Full text

, , +17